Mild Cognitive Impairment

Emory Alzheimer's Disease Research Center Honor Research Registry

James Lah, MD, PhD
Clinical Core Leader, Emory Alzheimer's Disease Research Center

Felicia Goldstein, PhD
Clinical Core Co-Leader, Emory Alzheimer's Disease Research Center

Link to study flyer »

The purpose of Honor is to have a group of volunteers who want to participate in future research studies on memory & thinking.    By joining Honor you will learn about new research studies that are seeking volunteers.  You will also receive our newsletter and invitations to educational events. 

All Honor volunteers must have a “study partner” accompany them to their research visit.  Your study partner will be asked questions about your memory and thinking.  They will also be asked about your day to day functioning.  A study partner is someone who has at least 10 hours of contact with you each week.

For more information about this research study, please call Erin Carter at 404-712-6838 or email erin.carter@emory.edu.


AbbVie

James Lah, MD, PhD

2-year study examining the safety and e cacy of an infusion of an antibody to the tau protein in subjects with a diagnosis of mild-to moderate Alzheimer’s disease. Tau is one of the proteins involved in cellular destruction in AD. Participants will be asked to undergo a PET scan, multiple MRIs, lumbar puncture, blood draws, and cognitive testing. 

For more information about this research study, please call Rebekah Rogers at 404-712-4234 or email rebekah.d.rogers@emory.edu.

Link to study website »


ADNI-3

Allan Levey, MD, PhD
Director, Emory Alzheimer's Disease Research Center
Emory University Department of Neurology

Long-term study (2-4 years) being conducted as part of the Alzheimer’s Disease Neuroimaging Initiative to characterize changes in the brain associated with MCI and AD. Subjects will under multiple MRI and PET scans, lumbar puncture, blood draws and cognitive testing. 

For more information about this research study, please call Becky Byram at 404-712-0195 or email rbyram@emory.edu.


CEDAR

Ihab Hajjar, MD

Link to study flyer »

CEDAR is examing the effects of candesartan vs placebo in mild cognitive impairment and Alzheimer’s disease. The study is recruiting people who are 50 years of age or older who have early or mild memory difficulties, do not have high blood pressure and do not take blood pressure medications. Study personnel will invite you to come to Emory for an evaluation to check if you are eligible. 

For more information about this research study, please call Maureen Okafor at 404-712-2881 or email m.o.okafor@emory.edu.

Link to study website »


CREAD

Allan Levey, MD, PhD

This clinical trial will test the experimental drug crenezumab in people with early to mild Alzheimer's disease. Investigators will assess the drug's safety and efficacy and evaluate any changes in participants' dementia rating and performance on neuropsychological tests.

For more information about this research study, please call Phyllis Vaughn at 404-712-6901 or email pvaughn@emory.edu.

Link to study website »


Daybreak

This multinational study is using a placebo or the study drug, LY3314814, to determine clinical e cacy. E ectiveness of drug treatment will be assessed using cognitive tests, as well as biological markers (MRI, PET, CSF, blood)

For more information about this research study, please call Aaron Milloy at 404-712-6855 or email aaron.m.milloy@emory.edu.


EMERGE

The purpose of this study is to find out if aducanumab slows the progression of cognitive and functional impairment in people diagnosed with Mild Cognitive Impairment (MCI). In this research study, participants will be infused monthly with the study drug in one of 2 dosages or placebo for 12 months, followed by an optional long-term extension in which all participants will receive study drug. Participants will undergo PET and MRI scans, blood tests, cognitive assessments, an optional lumbar puncture, and physical and neurological exams. 

For more information about this research study, please call Michelle Wiles at 404-778-0664 or email mkwiles@emory.edu.


EXERT

Whitney Wharton, PhD
Emory University Department of Neurology

Joe Nocera, PhD

18-month study to examine the effects of aerobic exercise on cognition. Subjects with a diagnosis of mild cognitive impairment will be randomly assigned to undergo aerobic exercise or stretching/balance/rang-of-motion training for 4 dyas/week for 12 months at a local YMCA. Participants will be asked to agree to an MRI scan and an optional lumbar puncture, as well as cognitive assessments, blood draws, and a 400-meter walking test.

For more information about this research study, please call Tamara Attis at 404-712-6914 or email tattis@emory.edu.


NeuroVision

This is a 2-day study of amyloid imaging in the retina. This proof-of-concept study is for people with normal cognition or MCI, AD or other neurodegenerative disease. This is a brief study in which participants will be asked to ingest the spice curcumin for 2 days. Curcumin binds to the protein associated with Alzheimer’s disease, and it is possible to visualize the protein by looking into the eyes. Photographs of the eyes will be after 2 days of ingesting curcumin. The pupils of the eyes will be dilated for this study.

For more information about this research study, please call CeeCee Manzanares at 404-727-9324 or email cmanzan@emory.edu.


VASCULAR

Ihab Hajjar, MD

Link to study flyer »

A 2-year observational study examining the relationship between vascular factors and memory loss. Healthy volunteers and people with a diagnosis of mild cognitive impairment are eligible for participation. Participants will come to Emory 4 times over 2 years and will undergo the following procedures: MRI, vascular ultrasound, lumbar puncture, cognitive testing, and blood draws. 

For more information about this research study, please call Tiffany Thomas at 404-712-3639 or email tlthom@emory.edu.

Link to study website »